Log in  First Connection?

BreastArchives

Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities
Breast
 6 min.

 Published on 02/12/2025 |  Original article (Full-text)  | Dong Huiyu et al. | Breast Cancer Research 2025; 27(1): 209

Obesity has become a global pandemic With the World Obesity Atlas 2024 projecting that over 54% of the world's adult population will be overweight or obese by 2035 based on BMI criteria [1]. Once prevalent mainly in developed nations, this metabolic disorder is now increasingly widespread in developing...

ACSL6 modulates docosahexaenoic acid-induced cytotoxicity to potentiate chemotherapy response in colorectal and breast cancer
Breast
 8 min.

 Published on 25/11/2025 |  Original article (Full-text)  | Chen I-Sung et al. | Oncogenesis 2025; 14(1): 45

Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to microenvironmental challenges, sustain proliferation, evade immune surveillance, and develop therapeutic resistance [1]. Emerging evidence underscores the pivotal role of lipid metabolism in cancer progression, where tumor...

The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer
Breast
 4 min.

 Published on 18/11/2025 |  Original article (Full-text)  | Loza Peteris et al. | BMC Cancer 2025; 25(1): 1767

Recent research indicates that the risks of primary breast cancer (PBC) and ovarian cancer (OC) in BRCA1 pathogenic variant (PV) carriers may vary depending on the specific mutation`s location within the gene. However, current evidence remains insufficient to modify clinical decisions regarding...

Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer
Breast
 6 min.

 Published on 11/11/2025 |  Original article (Full-text)  | Xie Guojing et al. | Breast Cancer Research 2025; 27(1): 197

Triple-negative breast cancer (TNBC), which is characterized by the expression of estrogen receptor (ER-), progesterone receptor (PR-), and human epidermal growth factor receptor 2 (HER2-), is an aggressive subtype of breast cancer. Although it accounts for 15–20% of all breast cancer patients,...

Optimising breast cancer screening in national mammography screening centres: challenges and insights on implementing additional ultrasound for women with dense breast tissue — a qualitative study
Breast
 7 min.

 Published on 04/11/2025 |  Original article (Full-text)  | Elsner Susanne A. et al. | BMC Cancer 2025; 25(1): 1682

The public breast cancer screening programme in Germany is aimed at women aged 50–75 years; the upper age limit was raised from 69 to 75 in July 2024. Eligible women are invited to participate in the programme every two years. Some studies suggest that public mammography screening is associated...